Palisade Bio Inc (PALI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palisade Bio Inc (PALI) has a cash flow conversion efficiency ratio of -0.062x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($121.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Palisade Bio Inc stock valuation for the company's overall valuation and market capitalisation.
Palisade Bio Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Palisade Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Palisade Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palisade Bio Inc ranked by their cash flow conversion efficiency. Explore Palisade Bio Inc (PALI) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lafayette Digital Acquisition Corp. I Class A Ordinary Shares
NASDAQ:ZKP
|
-0.002x |
|
Mitrabahtera Segara Sejati Tbk
JK:MBSS
|
49.540x |
|
Taimide Tech Inc
TW:3645
|
0.071x |
|
WCM Beteiligungs- und Grundbesitz-AG
F:WCMK
|
-0.005x |
|
Heung-A Shipping Co. Ltd.
KO:003280
|
0.034x |
|
Alico Inc
NASDAQ:ALCO
|
-0.052x |
|
Sidetrade
PA:ALBFR
|
0.086x |
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
0.010x |
Annual Cash Flow Conversion Efficiency for Palisade Bio Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Palisade Bio Inc from 2005 to 2025. View latest Palisade Bio Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $129.38 Million | $-10.85 Million | -0.084x | +94.85% |
| 2024-12-31 | $7.49 Million | $-12.19 Million | -1.627x | -65.38% |
| 2023-12-31 | $11.31 Million | $-11.13 Million | -0.984x | +8.08% |
| 2022-12-31 | $12.48 Million | $-13.36 Million | -1.071x | +46.63% |
| 2021-12-31 | $7.37 Million | $-14.77 Million | -2.006x | -398.65% |
| 2020-12-31 | $-7.10 Million | $-4.77 Million | 0.672x | +147.45% |
| 2019-12-31 | $5.13 Million | $-7.26 Million | -1.415x | -11.32% |
| 2018-12-31 | $6.05 Million | $-7.69 Million | -1.272x | +19.29% |
| 2017-12-31 | $8.52 Million | $-13.42 Million | -1.576x | -14.32% |
| 2016-12-31 | $11.33 Million | $-15.62 Million | -1.378x | +63.84% |
| 2015-12-31 | $4.97 Million | $-18.93 Million | -3.811x | -476.88% |
| 2014-12-31 | $17.72 Million | $-11.71 Million | -0.661x | +47.49% |
| 2013-12-31 | $8.42 Million | $-10.59 Million | -1.258x | -3.48% |
| 2012-12-31 | $6.97 Million | $-8.48 Million | -1.216x | +75.08% |
| 2011-12-31 | $1.66 Million | $-8.10 Million | -4.878x | -283.86% |
| 2010-12-31 | $7.85 Million | $-9.98 Million | -1.271x | -223.88% |
| 2009-12-31 | $-5.02 Million | $-5.14 Million | 1.026x | +162.85% |
| 2008-12-31 | $4.20 Million | $-6.86 Million | -1.632x | -177.74% |
| 2007-12-31 | $6.81 Million | $-4.00 Million | -0.588x | +72.65% |
| 2006-12-31 | $1.55 Million | $-3.33 Million | -2.148x | -235.69% |
| 2005-12-31 | $-460.17K | $-728.59K | 1.583x | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more